


Please Direct All Correspondence to Customer Number **30,313**



TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT

Applicant : Eaton, et al.
App. No : 10/063,561
Filed : May 2, 2002
For : SECRETED AND TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC ACIDS
ENCODING THE SAME
Examiner : Patricia Ann Duffy
Art Unit : 1645

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 28, 2005

(Date)

Daniel Hart, Reg. No. 40,637

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing two (2) references.
 - (X) Enclosing two (2) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Daniel Hart

Registration No. 40,637

Attorney of Record

Customer No. 30,313

(619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant : Eaton, et al.
App. No : 10/063,561
Filed : May 2, 2002
For : SECRETED AND
TRANSMEMBRANE POLYPEPTIDES
AND NUCLEIC ACIDS ENCODING
THE SAME
Examiner : Patricia Ann Duffy
Art Unit : 1645

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 28, 2005

(Date)

Daniel Hart, Reg. No. 40,637

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing two (2) references to be considered by the Examiner. Also enclosed are two (2) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 28, 2005

By:

Daniel Hart

Registration No. 40,637

Attorney of Record

Customer No. 30,313

(619) 235-8550



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary) SHEET 1 OF 1	Application No.	10/063,561
	Filing Date	May 2, 2002
	First Named Inventor	Eaton, et al.
	Art Unit	1645
	Examiner	Patricia Ann Duffy
	Attorney Docket No.	GNE.3230R1C41

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	FESSLER, et al. 2002. A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase. <i>The Journal of Biological Chemistry</i> , 277(35):31291-31302.	
	2	TOKUNAGA, et al. 2000. Application of quantitative RT-PCR using "TaqMan" technology to evaluate the expression of CK 18 mRNA in various cell lines. <i>J. Exp. Clin. Cancer Res.</i> , 19(3):375-381.	

1837057:dmb
072805

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.